| Recruiting | Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma Neuroblastoma | Phase 2 | 2024-12-06 |
| Recruiting | Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma Neuroblastoma | Phase 2 | 2022-09-14 |
| Recruiting | DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma Medulloblastoma | Phase 2 | 2021-03-29 |
| Recruiting | Beat Childhood Cancer Specimen Banking and Data Registry Pediatric Cancer, Survivorship | — | 2021-02-02 |
| Recruiting | Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma Neuroblastoma | Phase 2 | 2020-09-25 |
| Withdrawn | Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma Relapsed Neuroblastoma | N/A | 2017-05-01 |
| Recruiting | Neuroblastoma Maintenance Therapy Trial Neuroblastoma | Phase 2 | 2016-02-01 |
| Terminated | Trial of Tolcapone With Oxaliplatin for Neuroblastoma Neuroblastoma | Phase 1 | 2015-12-01 |
| Recruiting | Pediatric Precision Laboratory Advanced Neuroblastoma Therapy Neuroblastoma | Phase 2 | 2015-09-01 |
| Completed | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remis Neuroblastoma | Phase 2 | 2015-03-05 |
| Completed | Molecular-Guided Therapy for Childhood Cancer Neuroblastoma, Medulloblastoma, Glioma | N/A | 2014-07-08 |
| Completed | Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastom Neuroblastoma Recurrent | Phase 1 / Phase 2 | 2014-06-06 |
| Terminated | Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma Pontine Glioma | Phase 2 | 2013-05-01 |
| Completed | Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer Neuroblastoma, Medulloblastoma, Brain Tumors | N/A | 2013-03-04 |
| Terminated | Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma Neuroblastoma, Medulloblastoma | Phase 1 / Phase 2 | 2011-12-01 |
| Terminated | Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma Neuroblastoma | Phase 1 / Phase 2 | 2011-12-01 |
| Completed | Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma Neuroblastoma | N/A | 2011-05-01 |
| Completed | A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma Refractory Neuroblastoma, Relapsed Neuroblastoma | — | 2010-04-01 |
| Completed | Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide Neuroblastoma | Phase 1 | 2010-02-01 |
| Completed | TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma Neuroblastoma, Medulloblastoma, Relapse | Phase 1 | 2009-03-01 |
| Completed | Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma Neuroblastoma, Medulloblastoma | Phase 2 | 2008-01-14 |
| Available | An Intermediate Expanded Use Trial of DFMO Neuroblastoma, Medulloblastoma, Typical Teratoid Rhabdoid Tumor | — | — |